Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Israel's biotechnology industry is bottom heavy—big on ideas but, so far, not on accomplishments. It needs to get its investors and scientists to talk.
Singapore hopes to become the R&D and manufacturing hub for the East Asian biotechnology industry, but it may find that its past success in IT does not predict future success in biotechnology.
Once chilled by unfavorable economic policies, and depleted by a brain drain to the United States, Ontario is making a comeback in the business of biotechnology.
The targeted disruption of two genes in sheep confirms the feasibility of gene targeting in large animals, but falls short of producing viable offspring.
Left out of almost all reporting on the Canadian Federal Court's recent ruling in Monsanto v. Schmeiser were the implications of the decision on patenting plants—something that Canada has not permitted.